Table 3.
Treatment | Pericardial Sac Area (% Control Vehicle area) |
Body Length (% Control Vehicle Length) |
---|---|---|
Vehicle control | 100 ± 4.1 a | 100 ± 1.1 a |
DEM 50nM | 128.7 ± 3.9 a | 98.4 ± 0.5 a |
PCB126 25 nM | 329.5 ± 20.6 b | 94.1 ± 0.9 b |
PCB126 25 nM + DEM 50 nM | 302.5 ± 10.8 b | 93.7 ± 0.4 b |
Vehicle control | 100 ± 2.9 a | 100 ± 1.2 a |
NAC 100 µM | 88.3 ± 8.2 a | 101.2 ± 1.4 a |
PCB126 25 nM | 205.0 ± 21.5 b | 94.1 ± 0.5 b |
PCB126 25 nM + NAC 100 µM | 216.5 ± 24.4 b | 92.8 ± 0.9 b |
Vehicle control | 100 ± 4.9 a | 100 ± 0.8 a |
Lipoic acid 10 µM | 102.9 ± 2.9 a | 98.4 ± 1.0 a |
PCB126 25 nM | 271.6 ± 10.4 b | 93.9 ± 0.1 b |
PCB126 25 nM + lipoic acid 10 µM | 318.9 ± 39.4 b | 88.9 ± 0.8 b |
Vehicle control | 100 ± 3.1 a | 100 ± 0.1 a |
Quercetin 12 µM | 118 ± 6.4 a | 98.5 ± 0.6 a |
PCB126 25 nM | 350.5 ± 13.0 b | 91.5 ± 0.5 b |
PCB126 25 nM + quercetin 12 µM | 340.3 ± 26.4 b | 91.6 ± 1.0 b |
Vehicle control | 100 ± 10.1 a | 100 ± 0.3 a |
Indomethacin 30 µM | 114.9 ± 1.7 a | 96.5 ± 0.7 a |
PCB126 25 nM | 223.9 ± 19.2 b | 92.3 ± 0.5 b |
PCB126 25 nM + indomethacin 30 µM | 246.9 ± 22.8 b | 89.6 ± 1.3 b |